Replies to post #806317 on NorthWest Biotherapeutics Inc (NWBO)

[seekinganswers]

"Nope, not in the L trial"
How could you possibly know that after "crossover" when the placebo group was eliminated?

First of all, the P III L trial is completely flawed and was a major failure.
Crossover spilled coffee all over any potential results, and was likely done on purpose because DCVax wasn't working.
PFS also failed and then they changed that endpoint as well. Then they went to OS and that also failed which led them to use external controls that didn't match the trial cohorts so as to further corrupt and jury rig the trial results. It's also noteworthy that the external controls were NOT in the original trial design. Bottom line, it was a failed AND corrupt trial in my opinion and the opinion of many scientists, medical doctors and researchers. Why do you think it has been over 2 years now and the MAA was sent to CHM because it had "major objections" and was "precluded from approval" by MHRA???
Grok also says TTF is a beneficial adjuvant to increase survival outcomes. You literally do not know anything of which you speak about.

The standard of care for glioblastoma multiforme (GBM) typically involves maximal safe surgical resection followed by concurrent radiation therapy and temozolomide chemotherapy, then adjuvant temozolomide. Survival outcomes vary based on factors like age, performance status, tumor molecular features (e.g., MGMT methylation), and extent of resection, but key benchmarks from clinical trials and real-world data are as follows:Median overall survival: Approximately 14.6–16 months.
2-year survival rate: Around 26–30%.
5-year survival rate: Approximately 5–10%, with the landmark EORTC-NCIC trial reporting 9.8% for patients receiving this treatment regimen.
These figures represent treated patients in controlled settings; real-world outcomes may be slightly lower overall due to comorbidities or incomplete treatment adherence. Add-on therapies like tumor-treating fields can improve rates further (e.g., up to 13% at 5 years in some trials), but the query focuses on the core standard of care.

[Nemesis18]

Outside of the trial, the are patients diagnosed with GBM4 who have a survivorship >10 years, and still going strong (with just initial SOC.

Inside of the trial recruitment, with a very very careful selection of patients, it is very possible to make it appear that there was a slight advantage gained with this 'vaccine' -cough.

[exwannabe]

Nope, not in the L trial. But hey, what’s just one more false claim on top of the enormous pile of bashers’ lies found on this board?

If you mean internally to the trial, you are talking 30 patients with a preferential selection for unhealthy (patients who were in poor condition could not cross). So, yeah, 10 year OS would not be expected.

If you mean the ECA, you are flat out wrong. And if you think the 0 at risk implies that, you are still wrong.The NWBO reconstruction of the ECA data had no data past 60 months, so nobody was at risk of dying.

[Nemesis18]

The application was in major trouble the moment it was receipted by the Regulator, being almost in a continuous state of RFI for two years.
This level of scrutiny should only be applauded imo.